Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eisai To Resubmit Aricept Severe Alzheimer’s sNDA In December

This article was originally published in The Pink Sheet Daily

Executive Summary

Firm is considering changing from paper to electronic filing to resolve formatting issues behind FDA’s refusal to file the sNDA.

You may also be interested in...



Alzheimer’s Drugs Should Be Limited To Moderate Disease, U.K.’s NICE Says

National Institute for Health & Clinical Excellence recommends limited use of acetylcholinesterase inhibitors, finds against Namenda.

Alzheimer’s Drugs Should Be Limited To Moderate Disease, U.K.’s NICE Says

National Institute for Health & Clinical Excellence recommends limited use of acetylcholinesterase inhibitors, finds against Namenda.

Eisai Resubmits Aricept sNDA For Severe Alzheimer’s

Eisai has submitted a reformatted electronic supplemental new drug application for Aricept (donepezil), the firm announced Dec. 19

Related Content

Topics

UsernamePublicRestriction

Register

PS061184

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel